National and Kapodistrian University of Athens
Μελέτη του ρόλου των οιστρογόνων σε γνωστικές διαταραχές και σε διαταραχές διάθεσης: πειραματικές προσεγγίσεις σε θηλυκούς και αρσενικούς επίμυες
Abstract
dc:descriptionAromatase inhibitors, which are widely used in the clinic for the treatment of estrogen-dependent cancers, have been associated with psychiatric effects ranging from mania to depression. Aromatase is the rate-limiting enzyme that catalyzes the conversion of androgens to estrogens. It is mainly located in the ovaries in women, in the testes in men, as well as in the placenta and adrenals. However, it has been shown that other organs, such as the liver, bones, and importantly the brain can produce estrogens locally. Emerging evidence suggests that brain-derived estrogens are responsible for the fine-tuning of neuronal circuits in males and females. However, preclinical studies investigating the role of estrogens in depression and especially the role of brain-derived estrogens in males and females were missing from the scientific literature. Therefore, the aim of the present study was to investigate whether decreased estrogen synthesis following aromatase inhibition influences depressive symptomatology and underlying brain and hormonal mechanisms in rats. In the first experiment, we investigated whether treatment with the aromatase inhibitor letrozole leads to a depressive-like behavioral response in cycling female rats. Using the Forced Swim Test (FST) of antidepressant activity we estimated the effect of acute (1 mg/kg, i.p., 3 injections in 24 hours) and sustained (7 days) letrozole administration. The antidepressant fluoxetine was also administered, as a positive control. Testosterone and progesterone levels were assayed in the serum of all animals. Surprisingly, acute aromatase inhibition decreased immobility duration in the FST, indicating its antidepressant potential. Instead, sustained aromatase inhibition did not show such antidepressant potential. Testosterone elevation associated with the decreased depressive behavior in the FST following acute letrozole treatment, but interestingly progesterone explained the increased swimming behavior in cycling female rats. In a second experiment, we followed up the effects of chronic letrozole treatment on female animals and investigated whether such effects would be differentiated in ovariectomized female rats that lack gonadal-derived hormones. Furthermore, we performed all experiments at the same time in male rats, in order to investigate sex differences. In particular, we investigated the behavioral and neurochemical effects of aromatase inhibition on male and female sham-operated or gonadectomized adult rats. Three weeks later, rats received a chronic treatment of the aromatase inhibitor letrozole (1 mg/kg, i.p., once daily for one week) or vehicle and they were subjected to the open field and forced swim test (FST). Aromatase activity was determined in the hypothalamus and testosterone and corticosterone were assayed in the blood serum of all rats. The hippocampus and prefrontal cortex were analyzed for monoamine (noradrenaline, dopamine, serotonin and metabolites) and amino acids (GABA, glutamate, glycine, taurine alanine and histidine) levels. Letrozole treatment inhibited the aromatase enzyme in the brain, since aromatase activity in the hypothalamus was decreased in letrozole-treated rats. Also, testosterone levels were markedly enhanced in letrozole-treated, sham-operated females. FST exposure enhanced corticosterone levels in all groups. In the open field test, females were overall more active and explorative than males, whereas gonadectomy eliminated this sex difference. Aromatase inhibition had no effect in the open field test. In the FST, females exhibited overall higher immobility and lower swimming duration than males. Aromatase inhibition decreased noradrenaline levels and dopaminergic ratios in the hippocampus and PFC of male and female rats, irrespectively of gonadectomy. Other sex differences, as well as stress effects, due to FST exposure, were also apparent in the hippocampus and the prefrontal cortex. Regarding amino acids levels, letrozole had no major effects, but interesting sex differences were observed in the prefrontal cortex. The present findings mainly show that behavioral effects of aromatase inhibitors in the FST are heavily dependent on the duration of treatment. Behavioral findings could be further associated with serotonergic and dopaminergic changes in brain regions involved in depression. Importantly, the present data could be linked with the development of affective disorders in post-menopausal women treated with aromatase inhibitors and may have implications for women treated with aromatase inhibitors before menopause. Finally, they contribute to the elucidation of the role of gonadal hormones in the expression of depressive symptoms and antidepressant response.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2016
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Pastromas, Nikolaos
- Παστρωμάς, Νικόλαος
Subjects
dc:subject × 18Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/39670